Who's Who Legal
Who's Who Legal
New to Who's Who Legal?
New to Who's Who Legal?
Menu
User Menu
New to Who's Who Legal?
Thought Leaders

Thought Leaders

Thought Leader

WWL Ranking: Thought Leader
WWL Ranking: Thought Leader

Global Leader

WWL Ranking: Recommended

WWL says

Dieter Gericke is highly sought after by clients who praise his “top-quality work” as well as his “very broad knowledge of corporate law and equity transactions”.

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group and former co-head of the capital markets practice. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the takeover of Syngenta by ChemChina, the sale of Therachon Pharma to Pfizer, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the takeover bid of Temenos to Fidessa, the acquisition of Activ International by Givaudan, the IPO of Zur Rose Group and the financing of ADC Therapeutics. He is particularly experienced in the life sciences, engineering, technology and insurance industries

In his areas of practice, Dieter Gericke authored various publications, including on public M&A, securities laws, corporate governance and say-on-pay regulations. He is a member of the IBA corporate and M&A as well as the securities law committee.

Dieter Gericke is a member of the board of directors of Syngenta, a leading agrotechnology group, and of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries.

Corporate Governance 2020

Professional Biography

WWL Ranking: Recommended

WWL says

Dieter Gericke is a go-to lawyer for board members and listed companies thanks to his wealth of corporate governance experience.

Biography

Dieter Gericke heads Homburger’s corporate and M&A team, as well as its China group, and is the former co-head of the capital markets practice. He has a law degree and a doctorate from the University of Zurich, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on public and private M&A, equity capital markets (including IPOs), private equity and corporate governance. He advises in shareholder activism corporate law, as well as securities regulations.

Recent assignments include the takeover of Syngenta by ChemChina; the sale of Therachon Pharma to Pfizer; the financing and NASDAQ offering of ADC Therapeutics; the share issuance by AC Immune; the acquisition of Haas Group by Bühler Group; the acquisition of Kunststoff Schwanden by Bregal; the takeover bid of Temenos to Fidessa; the acquisition of Induchem by Givaudan; and the IPOs of Zur Rose Group. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke has authored various publications and chaired a number of panels, including those relating to public M&A, securities laws, corporate governance and say-on-pay regulations. He is a member of the IBA’s corporate/M&A and securities law committees.

Dieter Gericke is a board member of Gericke Group, which produces powder-processing equipment and systems for the food, pharmaceutical and chemical industries; and a former board member of Syngenta, a leading agrotechnology group.

Healthcare 2020

Professional Biography

WWL Ranking: Recommended

WWL says

Dieter Gericke is praised as a "knowledgeable, business-oriented and fast" practitioner who finds "sustainable, practical and sound solutions".

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group and is former co-head of the capital markets practice. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the takeover of Syngenta by ChemChina, the sale of Therachon Pharma to Pfizer, the financing and NASDAQ offering of ADC Therapeutics, the share issuance by AC Immune, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the takeover bid of Temenos to Fidessa, the acquisition of Activ International by Givaudan, the IPO of Zur Rose Group and the financing of ADC Therapeutics. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke authored various publications and chaired a number of panels, including on public M&A, securities laws, corporate governance and say-on-pay regulations. He is a member of the IBA corporate and M&A as well as the securities law committee.

Dieter Gericke is a member of the board of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries and a former member of the board of Syngenta, a leading agrotechnology group.

M&A 2020

Professional Biography

WWL Ranking: Recommended

WWL says

Dieter Gericke is highlighted for his “excellent business acumen” as well as his “profound expertise” and “skill in difficult negotiations”.

Biography

Dieter Gericke heads Homburger’s corporate and M&A team, as well as its China group, and is the former co-head of the capital markets practice. He has a law degree and a doctorate from the University of Zurich, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on public and private M&A, equity capital markets (including IPOs), private equity and corporate governance. He advises in shareholder activism corporate law, as well as securities regulations.

Recent assignments include the takeover of Syngenta by ChemChina; the sale of Therachon Pharma to Pfizer; the financing and NASDAQ offering of ADC Therapeutics; the share issuance by AC Immune; the acquisition of Haas Group by Bühler Group; the acquisition of Kunststoff Schwanden by Bregal; the takeover bid of Temenos to Fidessa; the acquisition of Induchem by Givaudan; and the IPOs of Zur Rose Group. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke has authored various publications and chaired a number of panels, including those relating to public M&A, securities laws, corporate governance and say-on-pay regulations. He is a member of the IBA’s corporate/M&A and securities law committees.

Dieter Gericke is a board member of Gericke Group, which produces powder-processing equipment and systems for the food, pharmaceutical and chemical industries; and a former board member of Syngenta, a leading agrotechnology group.

National Leader

WWL Ranking: Recommended

WWL says

Dieter Gericke is singled out by peers in the Swiss market as a go-to practitioner for IPO and financing matters.

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group and former co-head of the capital markets practice. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the takeover of Syngenta by ChemChina, the sale of Therachon Pharma to Pfizer, the financing and NASDAQ offering of ADC Therapeutics, the share issuance by AC Immune, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the takeover bid of Temenos to Fidessa, the acquisition of Activ International by Givaudan, the IPO of Zur Rose Group and the financing of ADC Therapeutics. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke authored various publications and chaired a number of panels, including on public M&A, securities laws, corporate governance and say-on-pay regulations. He is a member of the IBA corporate and M&A as well as the securities law committee.

Dieter Gericke is a member of the board of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries and a former member of the board of Syngenta, a leading agrotechnology group.

WWL Ranking: Recommended

WWL says

Dieter Gericke comes highly recommended by market commentators who compliment his “great capacity for analysis” adding, “He is always available, very analytical and has a lot of experience.”

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group and former co-head of the capital markets practice. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the takeover of Syngenta by ChemChina, the sale of Therachon Pharma to Pfizer, the financing and NASDAQ offering of ADC Therapeutics, the share issuance by AC Immune, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the takeover bid of Temenos to Fidessa, the acquisition of Activ International by Givaudan, the IPO of Zur Rose Group and the financing of ADC Therapeutics. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke authored various publications and chaired a number of panels, including on public M&A, securities laws, corporate governance and say-on-pay regulations. He is a member of the IBA corporate and M&A as well as the securities law committee.

Dieter Gericke is a member of the board of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries and a former member of the board of Syngenta, a leading agrotechnology group.

Switzerland - M&A 2020

Professional Biography

WWL Ranking: Recommended

WWL says

Dieter Gericke wins glowing praise from peers who highlight his “profound expertise and comprehensive experience” in M&A. They appreciate his “high-level legal understanding” and his “pragmatic and solution-orientated approach”.

Biography

Dieter Gericke heads the corporate and M&A team as well as the Homburger China group and former co-head of the capital markets practice. He studied law at the University of Zurich, where he graduated and accomplished his doctorate, both summa cum laude. In 1999, he graduated from Harvard Law School with an LLM.

Dieter Gericke's practice focuses on M&A (including public takeovers and defence), equity capital markets (including IPOs), private equity and financing. He advises in matters of corporate law and governance, as well as securities regulations. He is an authorised issuers' representative at the SIX Swiss Exchange.

Recent assignments include the takeover of Syngenta by ChemChina, the sale of Therachon Pharma to Pfizer, the financing and NASDAQ offering of ADC Therapeutics, the share issuance by AC Immune, the acquisition of Haas Group by Bühler Group, the acquisition of Kunststoff Schwanden by Bregal, the takeover bid of Temenos to Fidessa, the acquisition of Activ International by Givaudan, the IPO of Zur Rose Group and the financing of ADC Therapeutics. He is particularly experienced in the life sciences, engineering, technology and insurance industries.

In his areas of practice, Dieter Gericke authored various publications and chaired a number of panels, including on public M&A, securities laws, corporate governance and say-on-pay regulations. He is a member of the IBA corporate and M&A as well as the securities law committee.

Dieter Gericke is a member of the board of Gericke Group, which produces powder processing equipment and systems for food, pharma and chemical industries and a former member of the board of Syngenta, a leading agrotechnology group.

Law Business Research
Law Business Research Ltd
Meridian House, 34-35 Farringdon Street
London EC4A 4HL, UK
© Law Business Research Ltd 1998-2020. All rights reserved.
Company No.: 03281866